Marc Ferrante

Country flagBelgium

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (13)

Background/Objectives: Recent advancements have significantly enhanced our understanding of the interplay between inflammatory bowel disease (IBD) and reproductive health. While international organizations provide guidelines for best practices, translating them into actionable strategies is crucial. This study aimed to develop a comprehensive care pathway to enhance preconception counselling and support for patients with IBD in the perinatal period, ensuring they receive optimal expert care. Methods: We used the 7-phase model for the development of the care pathway. Results: The resulting care pathway, structured as a time–task matrix, outlines the required actions at preconception, during pregnancy, and in the postpartum period for women with IBD. The pathway provides a structured and multidisciplinary approach that addresses the unique needs of patients with IBD of childbearing age. It emphasizes holistic and personalized support throughout the preconception, pregnancy, and postpartum period. Conclusions: The development of this care pathway represents a significant advancement in the perinatal management of IBD. By offering multidisciplinary and individualized care, optimal maternal and infant outcomes are pursued, while establishing a new global standard for reproductive health and perinatal management.

Year:

2025

Background and Aims Inflammatory bowel disease (IBD) often affects multiple relatives, pointing toward shared genetic and/or environmental factors. This study evaluates the importance of known IBD risk variants, and of genetic determinants of smoking in such multiplex families. Methods We studied 65 IBD multiplex families, comprising 146 Crohn’s disease (CD), 33 ulcerative colitis (UC), and 111 unaffected relatives. All families had at least 3 affected first-degree relatives. Common variant and rare variant polygenic risk scores (PRS and rvPRS) in these individuals were calculated and compared to 2040 sporadic IBD cases (1198 CD, 842 UC) and 598 unrelated controls. Associations for PRS, rvPRS, and smoking PRS were assessed using univariable and multivariable models. Results Within multiplex families, unaffected relatives had lower PRS than affected relatives (P = 0.01), but still higher scores than unrelated controls (P = 0.01). Interestingly, rvPRS did not differ between affected and unaffected relatives. PRS and rvPRS showed substantial heterogeneity across families; for example 10 families (2 for rvPRS) had PRS below unrelated controls, while 27 (6 for rvPRS) scored above sporadic cases. No correlation was found between PRS and rvPRS at the individual or family level. Smoking-related PRS were not associated with familial IBD. Conclusions Multiplex IBD families show diverse genetic architecture, with almost half showing a high burden of common and/or rare risk variants. While genetic predispositions to smoking influences IBD risk in sporadic cases, it provides limited insights into familial IBD. These findings highlight the genetic complexity within multiplex families and the need for tailored research approaches such as risk stratification and genetic screening strategies.

Year:

2025

Background and Aims Extracellular RNAs (exRNAs), including in serum, show potential as noninvasive biomarkers. However, their (patho)physiological role is still not fully understood. In this study, we characterized serum exRNAs in patients with inflammatory bowel diseases (IBDs) and evaluated their ability to differentiate ulcerative colitis (UC) from Crohn’s disease (CD). Methods We profiled serum exRNAs from 26 IBD patients (15 UC, 11 CD) with active endoscopic disease. Using Small Input Liquid Volume Extracellular RNA-sequencing, we investigated co-expression networks followed by randomized generalized linear modeling. An independent cohort (n = 109 UC, n = 150 CD) was studied to assess the exRNA reflection within the inflamed colonic and ileal mucosa. Results We detected 41 910 exRNAs, capturing 80.9% of genes expressed in intestinal tissue. Network analysis identified 69 clusters, of which one correlated with the distinction between CD and UC (r = −0.70, adjusted P = .006), featuring GNA12 as a hub gene. Serum GNA12 showed no association with fecal calprotectin, disease duration, age, or sex, but did correlate with UC-specific encoding genes (P < .05). Modeling within this upregulated UC-cluster prioritized a signature of 8 exRNAs including GNA12, distinguishing UC from CD with an accuracy [95% CI] of 95.8% [86.7-100.0%]. This elevated 8-marker signature was mirrored in the inflamed UC colon, when compared to the inflamed CD colon and ileum, also when evaluated along the disease location spectrum (P < .05). Conclusions Liquid biopsies may represent a novel, noninvasive approach in IBD biomarker development. Although larger in-depth studies are needed, this proof-of-concept study bridges noninvasive measurements with established IBD mechanisms, offering a promising tool for accurately distinguishing CD from UC.

Year:

2025

Background Recent advancements have significantly enhanced our understanding of the interplay between inflammatory bowel disease (IBD) and reproductive health. While international organizations provide guidelines for best practices, translating them into actionable strategies is crucial. Aim This study aimed to develop a comprehensive care pathway to enhance preconception counselling and support for IBD patients in the perinatal period, ensuring they receive optimal expert care. Methods We used the 7-phase model for the development of the care pathway. Finding The resulting care pathway, structured as a time-task matrix, outlines the required actions at preconception, during pregnancy, and in the postpartum period for women with IBD. Discussion The pathway provides a structured and multidisciplinary approach that addresses the unique needs of IBD patients of childbearing age. It emphasizes holistic and personalized support throughout the preconception, pregnancy, and postpartum period. Conclusion The development of this care pathway represents a significant advancement in the perinatal management of IBD. By offering multidisciplinary and individualized care, optimal maternal and infant outcomes are pursued, while establishing a new global standard for reproductive health and perinatal management. Statement of significance Problem or issue Managing IBD in women of childbearing age, particularly those planning pregnancy or already pregnant, is complex and demands a multidisciplinary approach. What is already known International IBD guidelines outline best practices for managing IBD during pregnancy but implementing these in routine clinical poses significant challenges. What this paper adds The IBD INFANT Wish care pathway transforms existing guidelines into a structured and multidisciplinary framework, providing comprehensive support and expert care for IBD patients across the preconception, pregnancy, and postpartum period.

Year:

2025

Background and Aims Treating ulcerative colitis (UC) in patients with prior advanced therapy (AT) exposure may be challenging. We report the efficacy and safety of risankizumab, a monoclonal interleukin 23p19 antibody, in patients with UC and prior inadequate response or intolerance to AT (AT-IR). Methods In the 12-week phase 3 INSPIRE induction study, patients were randomized to intravenous risankizumab 1200 mg or placebo. Clinical responders were randomized to subcutaneous risankizumab 180 mg, risankizumab 360 mg, or placebo (risankizumab withdrawal) in the 52-week phase 3 COMMAND maintenance study. This post hoc analysis assessed outcomes by AT-IR status, number, and mechanism of action. AT included biologics, Janus kinase inhibitors, and sphingosine-1-phosphate receptor modulators. Results Efficacy analyses included 472 non-AT-IR and 503 AT-IR patients (induction), and 137 non-AT-IR and 411 AT-IR patients (maintenance). More patients achieved clinical remission per Adapted Mayo score with risankizumab 1200 mg versus placebo at induction week 12 (non-AT-IR, 29.7% versus 8.4%, nominal P < .0001; AT-IR, 11.4% versus 4.3%, nominal P = .0083); consistent with risankizumab 180 mg or risankizumab 360 mg versus placebo (withdrawal) at maintenance week 52 (non-AT-IR, 50.9% or 61.7% versus 31.1%, nominal P = .057 or P = .0033, respectively; AT-IR, 36.6% or 29.5% versus 23.2%, nominal P = .0159 or P = .2334, respectively). Risankizumab had increased efficacy over placebo, regardless of AT-IR number or mechanism of action, with higher efficacy rates for non-AT-IR compared to AT-IR. Safety results in non-AT-IR and AT-IR patients were generally comparable in both induction and maintenance. Conclusions Risankizumab was effective and well tolerated, regardless of prior AT-IR status. Clinical trial registration numbers INSPIRE [NCT03398148], COMMAND [NCT03398135].

Year:

2025

Background and Aims Radiological imaging is crucial for diagnosing and monitoring patients with inflammatory bowel diseases (IBD). With increasing awareness of radiation risks, imaging doses should be “as low as reasonably achievable,” with a risk level that one should try to stay underneath 75 mSv. However, real-world data on cumulative exposure are limited. We retrospectively analyzed the radiation exposure of patients with IBD in a Belgian tertiary referral center. Methods Radiation exposure examinations were reviewed using the electronic health records. Annual (AED) and cumulative effective dose (CED) were calculated. A sub-analysis of patients diagnosed after January 1, 2007 was performed, as detailed radiation doses were maintained prospectively from that date onwards. Results In total, 4333 IBD patients (2753 Crohn’s disease [CD], 1512 ulcerative colitis [UC]) were included. The median (Interquartile range [IQR]) AED was 0.47 (0.02-1.67) mSv/year, and higher in CD than in UC (0.59 [0.05-1.79] vs 0.28 [0.01-1.44] mSv/year, P = .855). CED ≥ 75 mSv was reached in 5.5% of patients after a median [IQR] of 24 [13-34] years of follow-up. Sub-analysis of 1754 patients diagnosed from 2007 showed a median (IQR) AED of 0.74 (0.02-2.76) mSv/year, again higher for CD than UC (1.16 [0.02-3.42] vs 0.29 [0.01-2.28] mSv/year, P = .189). Here, 3.3% reached a CED ≥ 75 mSv after a median (IQR) of 9 [6-12] years of follow-up. The most common reasons for radiation exposure were comorbidities like malignancy. Conclusions Up to 5.5% of IBD patients reached a CED ≥ 75 mSv. While most imaging decisions were deemed appropriate, caution against excessive radiation remains crucial.

Year:

2025

Background Proctocolectomy with ileal pouch-anal anastomosis is the treatment of choice for patients with ulcerative colitis with medical refractory disease or dysplasia. The aim of this research was to describe the evolution of ileal pouch-anal anastomosis surgery and surgical outcomes over a three-decade interval in a high-volume referral centre. Methods All consecutive patients undergoing ileal pouch-anal anastomosis for ulcerative colitis between 1990 and 2022 at the University Hospitals of Leuven were retrospectively included. Patients were divided into three interval arms (interval A 1990–2000, interval B 2001–2010 and interval C 2011–2022). The primary outcomes of interest were anastomotic leakage at 30 days and pouch failure. Results Overall, 492 patients were included. The use of preoperative advanced therapies increased over time (P < 0.001). An increase in laparoscopic procedures (23.2% in interval A, 66.4% in interval B, 86.0% in interval C; P < 0.001) and a shift towards delayed ileal pouch-anal anastomosis (colectomy-first approach with delayed ileal pouch-anal anastomosis construction: 23.0% in interval A, 40.9% in interval B, 85.8% in interval C; P < 0.001) were observed. Anastomotic leakage rate decreased from 16.7% (interval A) to 8.4% (interval C) (P = 0.04). Delayed ileal pouch-anal anastomosis was the most relevant factor in limiting leakage (OR 0.49 (95% c.i. 0.27 to 0.87); P = 0.016). Median follow-up was 7.5 years (interquartile range 2.5–16). Cumulative pouch failure incidence was 8.2%, not significantly different between the three intervals (P = 0.580). Anastomotic leakage was the only significant risk factor for pouch failure (HR 2.82 (95% c.i. 1.29 to 6.20); P = 0.010). Conclusion Significant changes in the management of ulcerative colitis patients occurred. Despite the widespread use of advanced therapies and the expanded surgical indications, anastomotic leakage rate decreased over time. In the context of a delayed ileal pouch-anal anastomosis, diverting ileostomy could be avoided in selected cases. Anastomotic leakage remains the most relevant risk factor for pouch failure. Pouch failure incidence remained stable over the years.

Year:

2024

Background The consumption of ultra-processed foods has increased significantly worldwide and is associated with the rise in inflammatory bowel diseases. However, any causative factors and their underlying mechanisms are yet to be identified. This study aimed to further elucidate whether different types of the dietary emulsifier carrageenan (CGN) can alter the permeability and inflammatory state of the intestinal epithelium. Methods Caco-2/HT29-MTX cocultures (n = 4) were exposed to either κ-, ι-, or λ-CGN (100 µg mL–1) for 24 hours. Organoid-derived monolayers from patients with Crohn’s Disease (CD) were exposed to κ-CGN (100 µg mL–1) for 48 hours (n = 10). In both models, an inflamed condition was established by adding a mix of inflammatory stimuli. Changes in permeability were measured by transepithelial electrical resistance (TEER). In the organoid-derived monolayers, cytokines were quantified in the apical and basolateral supernatant and gene expression was analyzed with RT-qPCR. Results None of the CGN subtypes altered permeability of non-inflamed or inflamed Caco-2/HT29-MTX cocultures. In organoid-derived monolayers, κ-CGN did not affect TEER, but induced alterations in the gene expression of tight junctions and mucus proteins. Expression of TNF, IL8, and IL1B increased upon κ-CGN stimulation, both in inflamed and non-inflamed monolayers. Cytokine release in the supernatant was increased by κ-CGN for IL-6, IL-13, IL-4, IL-2, and IL-10. Conclusions Dietary CGN caused upregulation of inflammatory markers and affected cytokine release of intestinal epithelial cells from CD patients, while permeability remained unaltered. When inflammation was already present, this pro-inflammatory effect was more pronounced, suggesting a role for dietary CGN during active CD.

Year:

2024

Background and Aims Normalization of high-sensitivity C-reactive protein (hs-CRP) and fecal calprotectin (FCP) are suggested as intermediate treatment targets for Crohn’s disease (CD). This analysis evaluates achievement of biomarker normalization and the relationship between improvements in biomarker concentrations and clinical and endoscopic outcomes among patients treated with risankizumab. Methods This post hoc analysis included patients with moderately to severely active CD and elevated baseline hs-CRP (>5 mg/L) or FCP (>250 µg/g) concentrations from the 12-week ADVANCE and MOTIVATE induction studies, and the 52-week FORTIFY maintenance study. We assessed the proportion of patients achieving biomarker normalization, defined as hs-CRP ≤5 mg/L and FCP ≤250 µg/g, and the association between achieving biomarker normalization and improved clinical and endoscopic outcomes. Results Among 748 patients with elevated baseline hs-CRP or FCP concentrations, higher proportions of patients treated with risankizumab vs placebo achieved normalization of hs-CRP (Week 12: placebo, 17.5%; risankizumab 600 mg, 48.5%; Week 52: placebo, 29.5%; risankizumab 180 mg, 45.2%; risankizumab 360 mg, 40.8%) and FCP (Week 12: placebo, 9.1%; risankizumab 600 mg, 26.0%; Week 52: placebo, 28.0%; risankizumab 180 mg, 43.0%; risankizumab 360 mg, 44.0%; nominal p < 0.05 vs placebo for all comparisons). Achievement of both clinical or endoscopic outcomes and improvement of biomarker concentrations occurred at higher rates among patients treated with risankizumab vs placebo, regardless of prior exposure to biologic therapies. Conclusions Risankizumab treatment led to sustained normalization of inflammatory biomarkers with improved clinical and endoscopic results. Clinical Trial Registration Number ADVANCE, NCT03105128; MOTIVATE, NCT03104413; FORTIFY, NCT03105102.

Year:

2024

Background Risankizumab is efficacious and well tolerated in adults with moderately to severely active Crohn's disease (CD). Aim To evaluate the corticosteroid‐sparing effect of risankizumab in CD. Methods During the 12‐week induction period, patients maintained stable baseline corticosteroid doses, up to 20 mg/day prednisone or equivalent. At week 0 of maintenance, a mandatory corticosteroid taper was started. This post hoc analysis evaluated corticosteroid‐free clinical and endoscopic outcomes at week 52 of maintenance; safety was also assessed. Results Of 889 patients randomised to induction with risankizumab 600 mg or placebo, 285 (32.1%) were taking baseline concomitant corticosteroids. Week 12 clinical remission and endoscopic response rates were greater for risankizumab 600 mg versus placebo, regardless of concomitant corticosteroid use. At week 52, 66.7%, 50.0% and 41.2% of patients taking risankizumab 180 mg, risankizumab 360 mg and (withdrawal) placebo, respectively, discontinued corticosteroids. Week 52 corticosteroid‐free clinical remission per stool frequency/abdominal pain score (risankizumab 180 mg [42.7%] or 360 mg [49.8%]; [withdrawal] placebo [39.0%]), corticosteroid‐free clinical remission per Crohn's Disease Activity Index (risankizumab 180 mg [51.0%] or 360 mg [49.5%]; [withdrawal] placebo [40.2%]), and corticosteroid‐free endoscopic response (risankizumab 180 mg [44.6%] or 360 mg [44.7%]; [withdrawal] placebo [20.7%]) rates were greater for risankizumab than placebo. Adverse event rates were generally similar, regardless of baseline corticosteroid use. Conclusions Efficacy of risankizumab 600 mg induction therapy was independent of concomitant corticosteroid use. Risankizumab 180 and 360 mg maintenance therapy yielded high rates of corticosteroid‐free clinical and endoscopic outcomes at week 52.

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Collaborators (17)

Tadakazu Hisamatsu

-

JAPAN
View details

Ilse Van Diest

Full Professor

KULeuven

BELGIUM
View details

Jean Fred Colombel

Professor of Medicine

Icahn School of Medicine at Mount Sinai

UNITED STATES
View details

Livia Guadagnoli

Research Assistant Professor

Northwestern University

UNITED STATES
View details

Kristel Van Calsteren

KU Leuven

BELGIUM
View details

Remo Panaccione

Director, Inflammatory Bowel disease Unit, Professor of Medicine

University of Calgary

CANADA
View details

Raja Atreya

University Hospital Erlangen

GERMANY
View details

Isabelle Cleynen

Associate professor

KU Leuven

BELGIUM
View details

Séverine Vermeire

University Hospitals Leuven

BELGIUM
View details

Britta Siegmund

-

GERMANY
View details

Geert D’Haens

-

NETHERLANDS
View details

Edouard Louis

University of Liege

BELGIUM
View details

Bram Verstockt

Assistant professor

KU Leuven

BELGIUM
View details

Christophe Matthys

Extraordinary Professor

KU Leuven

BELGIUM
View details

Vipul Jairath

Professor of Medicine

Western University

CANADA
View details

David Rubin

Professor

University of Chicago

UNITED STATES
View details

Stefan Schreiber

-

GERMANY
View details